Price of drugs subject of dispute on two continents

11/8/2004 | AllAfrica Global Media · Financial Times (free content)

Despite a new law ordering Germany's national health care system to pay for drugs at reference prices, those keyed to the lowest-priced alternative drugs, Pfizer said it will not reduce the amount it charges for Lipitor, sold in Germany as Sortis. To meet the demand of the new law, set to take effect in January, Pfizer said it would have to cut its price by 38%. As a result, subscribers to the national health plan will have to make up the difference. In South Africa, another argument over drug pricing has led the pharmaceutical industry and health plans to blame each other for the high price of medicines in that country.

View Full Article in:

AllAfrica Global Media · Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC